Vanguard Group Inc Silverback Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,488,293 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,488,293
Previous 3,464,952
0.67%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding SBTX
# of Institutions
197Shares Held
76.6MCall Options Held
112KPut Options Held
240K-
Ra Capital Management, L.P. Boston, MA10.9MShares$00.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY10.5MShares$00.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.29MShares$00.0% of portfolio
-
Black Rock Inc. New York, NY4.08MShares$00.0% of portfolio
-
Sr One Capital Management, LP4.01MShares$00.0% of portfolio
About Silverback Therapeutics, Inc.
- Ticker SBTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,473,800
- Description
- Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...